^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Solid Tumor
    Drug:HLX22 (HER2 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

    Excerpt:
    ...Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2...
    Trial ID:
    NCT03916094
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

    Published date:
    05/04/2023
    Excerpt:
    Enrolled patients aged 18 to 75 years with histologically confirmed HER2-overexpressing advanced or metastatic solid tumors received intravenous HLX22 once every 3 weeks at 3, 10, and 25 mg/kg...four (36.4%) had stable disease.
    DOI:
    10.1007/s10637-023-01338-7